Dendreon Corp (DNDN) 2.65 $DNDN
Global Hormone-Sensitive Prostate Cancer Global Clinical Trials Review 2014 - Profiles of 16 Top Organisations
M2 - Thu Apr 17, 5:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9m7lf5/hormonesensitive) has announced the addition of the "Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014 provides data on the Hormone-Sensitive Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hormone-Sensitive Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hormone-Sensitive Prostate Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies/Organisations Participating in Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials - Novartis AG - Ferring International Center S.A. - Johnson & Johnson - GlaxoSmithKline plc - Dendreon Corporation - CMX Research Inc. - National Cancer Institute - Massachusetts General Hospital - University of California, San Francisco - Azienda Provinciale per i Servizi Sanitari - Comprehensive Cancer Centers of Nevada - City of Hope National Medical Center - Oslo University Hospital - Keio University - Barbara Ann Karmanos Cancer Institute - University of Pennsylvania For more information visit http://www.researchandmarkets.com/research/9m...esensitive
Global Therapeutic Vaccines Market 2014-2018 with Agenus, Bavarian Nordic A/S, Dendreon, GSK & Novartis International Dominating
M2 - Wed Apr 16, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zb45f5/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering. The Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. The increase in technological advances and improved understanding of immunology and immunotherapy has enabled the discovery of many biomarkers, thus aiding the development of therapy through the body's natural defense mechanism. Vaccines are usually thought of as biologics, which elicit an immune response to initiate a defense mechanism. This led to the development of therapeutic vaccines, which can induce the immune system to attack the targeted diseased tissue with greater bioavailability and specificity with minimal side effects. Various strategies have been developed to make therapeutic vaccines viable alternatives to the existing therapeutic approaches. Thus, improved understanding of immunology and immunotherapy is expected to boost the growth of the Global Therapeutic Vaccines market. According to the report, the incidence of cancers, infectious diseases, and physiological disorders is widespread owing to poor lifestyle, low immunity, and unhygienic conditions. As a result, the incidence of disorders such as Alzheimer's disease, Parkinson's disease, cancer, diabetes, and infectious diseases such as Hepatitis B, HIV/AIDS, and HPV is rising. The manifestation of these ailments is expected to increase due to a rise in aging population. The use of these vaccines to treat such ailments will be boosted by an increase in prevalence of these diseases and disorders, thus boosting the growth of the market. Further, the report states that the stringent government regulations could lead to delays in production and additional manufacturing costs. Vendors transfer the burden of the extra costs onto the end-users, making the adoption of the vaccines challenging. Key Vendors - Agenus Inc. - Bavarian Nordic A/S. - Dendreon Corp. - GlaxoSmithKline plc - Novartis International AG Other Prominent Vendors - AFFiRiS AG. - Argos Therapeutics Inc. - Celldex Therapeutics Inc. - CEL-SCI Corp. - Cytos Biotechnology AG - GlobeImmune Inc. - NewLink Genetics Corp. - NovaRx Corp. - Oncothyreon Inc. - TVAX Biomedical Inc. - TapImmune Inc. - Vical Inc. - Vaccinogen Inc. Market Drivers/Trends/Challenges - Increase in Incidence of Cancer, Infectious Diseases, and Physiological Disorders - Ongoing Development of a Large Number of Therapeutic Vaccines - Stringent Regulations - Adverse Side Effects of Therapeutic Vaccines - Increase in Mergers and Acquisitions Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Pipeline Analysis - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zb45f5/global
5 Innovations Wall Street and Investors Don't Understand How to Value
Sean Williams, The Motley Fool - Motley Fool - Sun Apr 13, 10:31AM CDT
Innovation is the cornerstone to any successful business . From automakers and restaurants to mobile device makers and biotech companies, innovation is what separates one company from the next. It's also what drives revenue and profits for a company...
Immune Responses Enhanced and Sustained When PROVENGE(R) (sipuleucel-T) is Given After Androgen Deprivation Therapy in Biochemically-Recurrent Prostate Cancer
Business Wire - Fri Apr 11, 6:00AM CDT
April 11, 2014 - Dendreon Corporation (NASDAQ
NDN) today announced the presentation of preliminary data from a long-term analysis of the Phase II STAND study demonstrating that tumor-specific T-cell responses appear to be enhanced and sustained when PROVENGE(R) (sipuleucel-T) is given after androgen deprivation therapy (ADT) in patients with biochemically-recurrent prostate cancer (BRPC) at high risk for metastases. These data will be presented at the 29th Annual European Association of Urology (EAU) Congress taking place from April 11-15, 2014 in Stockholm, Sweden.(1)
5 Biotechs With Prostate Cancer Treatments Worth Watching
George Budwell, The Motley Fool - Motley Fool - Sat Apr 05, 4:30PM CDT
In the United States, prostate cancer is now the most common type of malignancy detected in men. Even more concerning is that prostate cancer has crept up to the second-leading cause of cancer-specific deaths among men in the U.S., according to...
Why I Bought Exelixis
Sean Williams, The Motley Fool - Motley Fool - Fri Apr 04, 11:05AM CDT
Some days as a biotech investor, no matter how savvy you think you are, you just have to bury your head in the sand because you're bound to experience a bad day. That's what happened last week to shareholders of Exelixis , a company I've been very...
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014
M2 - Wed Apr 02, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qc2v39/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Sanofi - Johnson & Johnson - Novartis AG - Astellas Pharma Inc. - Takeda Pharmaceutical Company Limited - Bristol-Myers Squibb Company - Bayer AG - Medivation, Inc. - AstraZeneca PLC - Dendreon Corporation Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - University of California, San Francisco - Memorial Sloan Kettering Cancer Center - Duke University - Barbara Ann Karmanos Cancer Institute - Swiss Group for Clinical Cancer Research - University of Wisconsin Madison - Stanford University For more information visit http://www.researchandmarkets.com/research/qc2v39/hormone
The Global Vaccine Market Forecast is Expected to Grow at a CAGR of around 12% during 2012-2017
M2 - Fri Mar 28, 10:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/87zbl9/global_vaccine) has announced the addition of the "Global Vaccine Market Forecast to 2017" report to their offering. Of late, the vaccines market is burgeoning with immense activities. Big pharmaceutical companies like GSK, Pfizer, Merck etc. are struggling to maintain their revenue and operating incomes amidst patent cliffs of blockbuster drugs. In such a scenario, vaccines, which have high entry barriers for generic players and the potential to generate blockbuster sales, are increasingly alluring the players. Besides, the market has also gained momentum due to the recent technological advances that now allow the manufacturing of high efficacy combination vaccines, providing protection from a plethora of diseases in one schedule. This has resulted in the introduction of several promising vaccines, actively promoted by health agencies and non-profit organizations to offer maximum immunization coverage, especially in the developing regions with high incidence rates of infectious diseases. In the report, the vaccine market has been studied on three distinct levels: Regional, Therapeutic Category, and Company. For regional analysis, key vaccine markets that together constitute around 90% of the global market, have been profiled. Further, the market has been broken down into 16 distinct therapeutic categories and their current and future outlook to 2017 has been analyzed. Through this, our analysts have conducted a thorough opportunity assessment in various therapeutic categories and regions to clearly highlight avenues which offer maximum opportunities for growth. Companies Mentioned: - AstraZeneca Plc. - Baxter International Inc. - BioCSL (CSL Biotherapies) - Crucell - Dendreon Corporation - Emergent Biosolutions - GSK - Merck - Novartis - Pfizer - Sanofi-Pasteur - Takeda Pharmaceutical Company Limited For more information visit http://www.researchandmarkets.com/research/87...al_vaccine About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Pre-Market Pulse - Health Care Sector Stocks -- Research on Exelixis, StemCells, Dendreon, and Vivus
PR Newswire - Mon Mar 24, 9:46AM CDT
On Friday, March 20, 2014, the NASDAQ Composite ended at 4,276.79, down 0.98%, the Dow Jones Industrial Average fell by 0.17% to close at 16,302.77, and the S&P 500 finished at 1,866.52, down 0.29%. Four out of ten sectors ended the session in negative. During the session gains in the Utilities, Materials and Energy sectors positively impacted the broader market, while significant retraction came in from Health Care, Consumer Discretionary and Information Technology sectors. The S&P 500 Heath Care Sector Index finished the day at 675.70, down 1.54%, while the same has gained 5.90% in the last three months. Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), StemCells Inc. (NASDAQ: STEM), Dendreon Corp. (NASDAQ: DNDN) and Vivus Inc. (NASDAQ: VVUS). Free technical research on EXEL, STEM, DNDN and VVUS can be downloaded upon signing up at:
Cancer Vaccines: Doomed to Fail?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Mar 24, 8:30AM CDT
Some ideas sound good in theory but just never manage to work out in real-world experience, and cancer vaccines are on their way to that destination. Following the failures of Vical and Merck KGaA with their respective cancer vaccines, ...
Medivation, Inc: Fast Growing Drugs That May Become Blockbusters
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 21, 1:30PM CDT
Blockbuster status -- the gold medal term awarded to therapies racking up sales of more than $1 billion per year -- is the Holy Grail for drug developers. Arguably, it's the chance to discover blockbusters that fuels industry R&D spend and...
Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors
GlobeNewswire - Tue Mar 18, 7:00AM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today announced the appointment of John H. Johnson to its board of directors effective March 26, 2014. Mr. Johnson currently serves as chairman, president and chief executive officer of Dendreon Corporation.
Biotech Earnings Checkup: CLDX, DNDN, OPX
George Budwell, The Motley Fool - Motley Fool - Thu Mar 06, 5:30PM CST
Earnings are the lifeblood of a company. They speak to a company's past, present, and most importantly for investors, future. And they give an important window into the overall health of a company. So, with that in mind, let's dig into the earnings...
'Fast Money' Recap: China Syndrome
at The Street - Thu Mar 06, 4:00AM CST
The trading panel discussed how to invest in and around China.
Today's Dead Cat Bounce Stock Is Dendreon (DNDN)
at The Street - Wed Mar 05, 1:01PM CST
Trade-Ideas LLC identified Dendreon (DNDN) as a "dead cat bounce" (down big yesterday but up big today) candidate
Price Movements, Clinical Trial Results, and Solid Financial Reports - Analyst Notes on Pfizer, Dendreon, DepoMed, Globus Medical, and Array
PR Newswire - Wed Mar 05, 12:13PM CST
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Dendreon Corp. (NASDAQ: DNDN), DepoMed Inc. (NASDAQ: DEPO), Globus Medical, Inc. (NYSE: GMED), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Biotech Stock Roundup: InterMune Grabs Headlines with Impressive Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 05, 9:58AM CST
Last week saw companies like Medivation, Arena and VIVUS reporting fourth quarter results. But, the spotlight remained on InterMune with its late-stage data on Esbriet.
Dendreon Corp.: The Biggest Loser in Biotech Today
David Williamson, The Motley Fool - Motley Fool - Tue Mar 04, 6:57PM CST
After popping 15% yesterday after the company released earnings, shares of Dendreon Corp . slipped back 7% today, showing that investors may have sobered up after taking time to digest the earnings news. The company did sell more of its drug...
Is Medivation Inc's Recent Pullback an Entry Opportunity?
Cory Renauer, The Motley Fool - Motley Fool - Tue Mar 04, 5:30PM CST
Medivation reported fourth quarter 2013 earnings after the bell on February 27 that beat estimates on both the top and bottom lines. Fourth quarter revenue grew 163% on year to $96.61 million, beating estimates by almost $24 million. While the...
Narrower-than-Expected Loss at Dendreon Drives Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 9:40AM CST
Dendreon reported 4Q13 loss of 23 cents per share, narrower than the Zacks Consensus Estimate of a loss of 37 cents per share
Global Hormone-Sensitive Prostate Cancer Global Clinical Trials Review 2014 - Profiles of 16 Top Organisations
M2 - Thu Apr 17, 5:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9m7lf5/hormonesensitive) has announced the addition of the "Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014 provides data on the Hormone-Sensitive Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hormone-Sensitive Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hormone-Sensitive Prostate Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies/Organisations Participating in Hormone-Sensitive Prostate Cancer Therapeutics Clinical Trials - Novartis AG - Ferring International Center S.A. - Johnson & Johnson - GlaxoSmithKline plc - Dendreon Corporation - CMX Research Inc. - National Cancer Institute - Massachusetts General Hospital - University of California, San Francisco - Azienda Provinciale per i Servizi Sanitari - Comprehensive Cancer Centers of Nevada - City of Hope National Medical Center - Oslo University Hospital - Keio University - Barbara Ann Karmanos Cancer Institute - University of Pennsylvania For more information visit http://www.researchandmarkets.com/research/9m...esensitive
Global Therapeutic Vaccines Market 2014-2018 with Agenus, Bavarian Nordic A/S, Dendreon, GSK & Novartis International Dominating
M2 - Wed Apr 16, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zb45f5/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering. The Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. The increase in technological advances and improved understanding of immunology and immunotherapy has enabled the discovery of many biomarkers, thus aiding the development of therapy through the body's natural defense mechanism. Vaccines are usually thought of as biologics, which elicit an immune response to initiate a defense mechanism. This led to the development of therapeutic vaccines, which can induce the immune system to attack the targeted diseased tissue with greater bioavailability and specificity with minimal side effects. Various strategies have been developed to make therapeutic vaccines viable alternatives to the existing therapeutic approaches. Thus, improved understanding of immunology and immunotherapy is expected to boost the growth of the Global Therapeutic Vaccines market. According to the report, the incidence of cancers, infectious diseases, and physiological disorders is widespread owing to poor lifestyle, low immunity, and unhygienic conditions. As a result, the incidence of disorders such as Alzheimer's disease, Parkinson's disease, cancer, diabetes, and infectious diseases such as Hepatitis B, HIV/AIDS, and HPV is rising. The manifestation of these ailments is expected to increase due to a rise in aging population. The use of these vaccines to treat such ailments will be boosted by an increase in prevalence of these diseases and disorders, thus boosting the growth of the market. Further, the report states that the stringent government regulations could lead to delays in production and additional manufacturing costs. Vendors transfer the burden of the extra costs onto the end-users, making the adoption of the vaccines challenging. Key Vendors - Agenus Inc. - Bavarian Nordic A/S. - Dendreon Corp. - GlaxoSmithKline plc - Novartis International AG Other Prominent Vendors - AFFiRiS AG. - Argos Therapeutics Inc. - Celldex Therapeutics Inc. - CEL-SCI Corp. - Cytos Biotechnology AG - GlobeImmune Inc. - NewLink Genetics Corp. - NovaRx Corp. - Oncothyreon Inc. - TVAX Biomedical Inc. - TapImmune Inc. - Vical Inc. - Vaccinogen Inc. Market Drivers/Trends/Challenges - Increase in Incidence of Cancer, Infectious Diseases, and Physiological Disorders - Ongoing Development of a Large Number of Therapeutic Vaccines - Stringent Regulations - Adverse Side Effects of Therapeutic Vaccines - Increase in Mergers and Acquisitions Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Pipeline Analysis - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zb45f5/global
5 Innovations Wall Street and Investors Don't Understand How to Value
Sean Williams, The Motley Fool - Motley Fool - Sun Apr 13, 10:31AM CDT
Innovation is the cornerstone to any successful business . From automakers and restaurants to mobile device makers and biotech companies, innovation is what separates one company from the next. It's also what drives revenue and profits for a company...
Immune Responses Enhanced and Sustained When PROVENGE(R) (sipuleucel-T) is Given After Androgen Deprivation Therapy in Biochemically-Recurrent Prostate Cancer
Business Wire - Fri Apr 11, 6:00AM CDT
April 11, 2014 - Dendreon Corporation (NASDAQ
NDN) today announced the presentation of preliminary data from a long-term analysis of the Phase II STAND study demonstrating that tumor-specific T-cell responses appear to be enhanced and sustained when PROVENGE(R) (sipuleucel-T) is given after androgen deprivation therapy (ADT) in patients with biochemically-recurrent prostate cancer (BRPC) at high risk for metastases. These data will be presented at the 29th Annual European Association of Urology (EAU) Congress taking place from April 11-15, 2014 in Stockholm, Sweden.(1) 5 Biotechs With Prostate Cancer Treatments Worth Watching
George Budwell, The Motley Fool - Motley Fool - Sat Apr 05, 4:30PM CDT
In the United States, prostate cancer is now the most common type of malignancy detected in men. Even more concerning is that prostate cancer has crept up to the second-leading cause of cancer-specific deaths among men in the U.S., according to...
Why I Bought Exelixis
Sean Williams, The Motley Fool - Motley Fool - Fri Apr 04, 11:05AM CDT
Some days as a biotech investor, no matter how savvy you think you are, you just have to bury your head in the sand because you're bound to experience a bad day. That's what happened last week to shareholders of Exelixis , a company I've been very...
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014
M2 - Wed Apr 02, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qc2v39/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Sanofi - Johnson & Johnson - Novartis AG - Astellas Pharma Inc. - Takeda Pharmaceutical Company Limited - Bristol-Myers Squibb Company - Bayer AG - Medivation, Inc. - AstraZeneca PLC - Dendreon Corporation Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - University of California, San Francisco - Memorial Sloan Kettering Cancer Center - Duke University - Barbara Ann Karmanos Cancer Institute - Swiss Group for Clinical Cancer Research - University of Wisconsin Madison - Stanford University For more information visit http://www.researchandmarkets.com/research/qc2v39/hormone
The Global Vaccine Market Forecast is Expected to Grow at a CAGR of around 12% during 2012-2017
M2 - Fri Mar 28, 10:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/87zbl9/global_vaccine) has announced the addition of the "Global Vaccine Market Forecast to 2017" report to their offering. Of late, the vaccines market is burgeoning with immense activities. Big pharmaceutical companies like GSK, Pfizer, Merck etc. are struggling to maintain their revenue and operating incomes amidst patent cliffs of blockbuster drugs. In such a scenario, vaccines, which have high entry barriers for generic players and the potential to generate blockbuster sales, are increasingly alluring the players. Besides, the market has also gained momentum due to the recent technological advances that now allow the manufacturing of high efficacy combination vaccines, providing protection from a plethora of diseases in one schedule. This has resulted in the introduction of several promising vaccines, actively promoted by health agencies and non-profit organizations to offer maximum immunization coverage, especially in the developing regions with high incidence rates of infectious diseases. In the report, the vaccine market has been studied on three distinct levels: Regional, Therapeutic Category, and Company. For regional analysis, key vaccine markets that together constitute around 90% of the global market, have been profiled. Further, the market has been broken down into 16 distinct therapeutic categories and their current and future outlook to 2017 has been analyzed. Through this, our analysts have conducted a thorough opportunity assessment in various therapeutic categories and regions to clearly highlight avenues which offer maximum opportunities for growth. Companies Mentioned: - AstraZeneca Plc. - Baxter International Inc. - BioCSL (CSL Biotherapies) - Crucell - Dendreon Corporation - Emergent Biosolutions - GSK - Merck - Novartis - Pfizer - Sanofi-Pasteur - Takeda Pharmaceutical Company Limited For more information visit http://www.researchandmarkets.com/research/87...al_vaccine About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Pre-Market Pulse - Health Care Sector Stocks -- Research on Exelixis, StemCells, Dendreon, and Vivus
PR Newswire - Mon Mar 24, 9:46AM CDT
On Friday, March 20, 2014, the NASDAQ Composite ended at 4,276.79, down 0.98%, the Dow Jones Industrial Average fell by 0.17% to close at 16,302.77, and the S&P 500 finished at 1,866.52, down 0.29%. Four out of ten sectors ended the session in negative. During the session gains in the Utilities, Materials and Energy sectors positively impacted the broader market, while significant retraction came in from Health Care, Consumer Discretionary and Information Technology sectors. The S&P 500 Heath Care Sector Index finished the day at 675.70, down 1.54%, while the same has gained 5.90% in the last three months. Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), StemCells Inc. (NASDAQ: STEM), Dendreon Corp. (NASDAQ: DNDN) and Vivus Inc. (NASDAQ: VVUS). Free technical research on EXEL, STEM, DNDN and VVUS can be downloaded upon signing up at:
Cancer Vaccines: Doomed to Fail?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Mon Mar 24, 8:30AM CDT
Some ideas sound good in theory but just never manage to work out in real-world experience, and cancer vaccines are on their way to that destination. Following the failures of Vical and Merck KGaA with their respective cancer vaccines, ...
Medivation, Inc: Fast Growing Drugs That May Become Blockbusters
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 21, 1:30PM CDT
Blockbuster status -- the gold medal term awarded to therapies racking up sales of more than $1 billion per year -- is the Holy Grail for drug developers. Arguably, it's the chance to discover blockbusters that fuels industry R&D spend and...
Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors
GlobeNewswire - Tue Mar 18, 7:00AM CDT
Portola Pharmaceuticals (Nasdaq
TLA) today announced the appointment of John H. Johnson to its board of directors effective March 26, 2014. Mr. Johnson currently serves as chairman, president and chief executive officer of Dendreon Corporation. Biotech Earnings Checkup: CLDX, DNDN, OPX
George Budwell, The Motley Fool - Motley Fool - Thu Mar 06, 5:30PM CST
Earnings are the lifeblood of a company. They speak to a company's past, present, and most importantly for investors, future. And they give an important window into the overall health of a company. So, with that in mind, let's dig into the earnings...
'Fast Money' Recap: China Syndrome
at The Street - Thu Mar 06, 4:00AM CST
The trading panel discussed how to invest in and around China.
Today's Dead Cat Bounce Stock Is Dendreon (DNDN)
at The Street - Wed Mar 05, 1:01PM CST
Trade-Ideas LLC identified Dendreon (DNDN) as a "dead cat bounce" (down big yesterday but up big today) candidate
Price Movements, Clinical Trial Results, and Solid Financial Reports - Analyst Notes on Pfizer, Dendreon, DepoMed, Globus Medical, and Array
PR Newswire - Wed Mar 05, 12:13PM CST
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Dendreon Corp. (NASDAQ: DNDN), DepoMed Inc. (NASDAQ: DEPO), Globus Medical, Inc. (NYSE: GMED), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Biotech Stock Roundup: InterMune Grabs Headlines with Impressive Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 05, 9:58AM CST
Last week saw companies like Medivation, Arena and VIVUS reporting fourth quarter results. But, the spotlight remained on InterMune with its late-stage data on Esbriet.
Dendreon Corp.: The Biggest Loser in Biotech Today
David Williamson, The Motley Fool - Motley Fool - Tue Mar 04, 6:57PM CST
After popping 15% yesterday after the company released earnings, shares of Dendreon Corp . slipped back 7% today, showing that investors may have sobered up after taking time to digest the earnings news. The company did sell more of its drug...
Is Medivation Inc's Recent Pullback an Entry Opportunity?
Cory Renauer, The Motley Fool - Motley Fool - Tue Mar 04, 5:30PM CST
Medivation reported fourth quarter 2013 earnings after the bell on February 27 that beat estimates on both the top and bottom lines. Fourth quarter revenue grew 163% on year to $96.61 million, beating estimates by almost $24 million. While the...
Narrower-than-Expected Loss at Dendreon Drives Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 9:40AM CST
Dendreon reported 4Q13 loss of 23 cents per share, narrower than the Zacks Consensus Estimate of a loss of 37 cents per share
